SKYCLARYS is a prescription medicine indicated for the treatment of FA in adults and adolescents aged 16 years and older.1

Get patients started with SKYCLARYS
The first and only FDA-approved prescription medicine to treat FA progression1,2

In studies, SKYCLARYS improved1:
These exploratory analyses should be interpreted cautiously given the limitations of data collected outside of a controlled study, which may be subject to confounding.

References:
1. Skyclarys. Prescribing Information. Reata Pharmaceuticals, Inc.; 2023.
2. Lynch DR, Chin MP, Delatycki
MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol.
2021;89(2):212-225. 3. Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical
features of
Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126(suppl 1):103-117. 4.
Schulz
JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat
Rev
Neurol. 2009;5(4):222-234. 5. Rummey C, Farmer JM, Lynch DR. Predictors of loss of
ambulation in
Friedreich’s ataxia. EClinical Medicine. 2020;18:1-9. 6. Rummey C, Corben LA,
Delatycki MB, et al.
Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet. 2019;5(6):371.
7. Patel M,
Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years.
Ann
Clin Transl Neurol. 2016;3(9):684-694. 8. Lynch DR, Chin MP, Boesch S, et al.
Efficacy of omaveloxolone in
Friedreich’s ataxia: delayed-start analysis of the MOXIe extension. Mov Disord. Published online
November
29, 2022. doi://10.1002/mds.29286 9. Galea CA, Huq A, Lockhart PJ, et al. Compound
heterozygous FXN
mutations and clinical outcome in Friedreich ataxia. Ann Neurol. 2016;79(3):485-495.
10. Fogel BL, Perlman
S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet
Neurol.
2007;6(3):245-257. 11. Wallace SE, Bird TD. Molecular genetic testing for hereditary
ataxia: what every
neurologist should know. Neurol Clin Pract. 2018;8(1):27-32. 12. Lynch DR,
Goldsberry A, Rummey C, et al.
Direct utility of natural history data in analysis of clinical trials: propensity match-based analysis of
omaveloxolone in Friedreich ataxia using the FA-COMS dataset. Preprint. Posted online August 16, 2022.
medRxiv 2022.08.12.22278684. doi: https://doi.org/10.1101/2022.08.12.22278684 13.
Beaulieu-Jones BK,
Finlayson SG, Yuan W, et al. Examining the use of real-world evidence in the regulatory process. Clin
Pharmacol Ther. 2020;107(4):843-852.